Lymphangiogenesis and tumor metastasis

Summary

In several human cancers, increased expression in primary tumors of vascular endothelial growth factor-C (VEGF-C) is correlated with regional lymph node metastasis. Studies using transgenic mice overexpressing VEGF-C, or xenotransplantation of VEGF-C-expressing tumor cells into immunodeficient mice, have demonstrated a role for VEGF-C in tumor lymphangiogenesis and the subsequent formation of lymph node metastasis. However, at variance with data obtained in animal models, there is at present very little evidence for lymphangiogenesis in human tumors. Nonetheless, the striking correlation between levels of VEGF-C in primary human tumors and lymph node metastases exists, which suggests that VEGF-C may serve functions other than lymphangiogenesis. Thus, VEGF-C may activate pre-existing lymphatics which in turn become directly involved in tumor cell chemotaxis, intralymphatic intravasation and distal dissemination. A reciprocal dialogue is therefore likely to exist between tumor and lymphatic endothelial cells which results in the formation of lymph node metastases.

This publication was partially financed by Serono Foundation for the Advancement of Medical Science.

Part of this paper was originally presented at the 2^nd International Workshop on New Therapeutic Targets in Vascular Biology from February 6-9, 2003 in Geneva, Switzerland.

Keywords

Cancer - metastasis - lymphatic - lymphangiogenesis - lymph node - cytokine - VEGF-C - VEGF-D - VEGFR-3

• References

• 1 Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality?. Clin Cancer Res 2001; 7: 462-8.
• 2 Stacker SA, Achen MG, Jussila L. et al. Metastasis: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-83.
• 3 Partanen TA, Arola J, Saaristo A. et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. Faseb J 2000; 14: 2087-96.
• 4 Sleeman JP, Krishnan J, Kirkin V. et al. Markers for the lymphatic endothelium: in search of the holy grail?. Microsc Res Tech 2001; 55: 61-9.
• 5 Gale N, Thurston G, Hackett S. et al. Angiopoietin-2 is required for postnatal angio-genesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002; 3: 411-23.
• 6 Yuan L, Moyon D, Pardanaud L. et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002; 129: 4797-806.
• 7 Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769-78.
• 8 Kubo H, Cao R, Brakenhielm E. et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibro-blast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 2002; 99: 8868-8873.
• 9 Oh SJ, Jeltsch MM, Birkenhager R. et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangio-genesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997; 188: 96-109.
• 10 Papoutsi M, Siemeister G, Weindel K. et al. Active interaction of human A375 melanoma cells with the lymphatics in vivo. Histochem Cell Biol 2000; 114: 373-385.
• 11 Papoutsi M, Sleeman JP, Wilting J. Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane. Microsc Res Tech 2001; 55: 100-7.
• 12 Yoon YS, Murayama T, Gravereaux E. et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 2003; 111: 717-25.
• 13 Szuba A, Skobe M, Karkkainen MJ. et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. Faseb J 2002; 16: 1985-7.
• 14 Enholm B, Karpanen T, Jeltsch M. et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res 2001; 88: 623-9.
• 15 Byzova TV, Goldman CK, Jankau J. et al. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 2002; 99: 4434-42.
• 16 Jeltsch M, Kaipainen A, Joukov V. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423-5.
• 17 Veikkola T, Jussila L, Makinen T. et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangio-genesis in transgenic mice. Embo J 2001; 20: 1223-31.
• 18 Dumont DJ, Jussila L, Taipale J. et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946-9.
• 19 Makinen T, Jussila L, Veikkola T. et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
• 20 Karkkainen MJ, Saaristo A, Jussila L. et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A 2001; 98: 12677-82.
• 21 Saaristo A, Veikkola T, Tammela T. et al. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med 2002; 196: 719-30.
• 22 Cao Y, Linden P, Farnebo J. et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A 1998; 95: 14389-94.
• 23 Paavonen K, Puolakkainen P, Jussila L. et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 2000; 156: 1499-504.
• 24 Kubo H, Fujiwara T, Jussila L. et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angio-genesis. Blood 2000; 96: 546-53.
• 25 Salven P, Lymboussaki A, Heikkila P. et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998; 153: 103-8.
• 26 Amioka T, Kitadai Y, Tanaka S. et al. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer 2002; 38: 1413-9.
• 27 Furudoi A, Tanaka S, Haruma K. et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 2002; 62: 157-66.
• 28 Achen MG, Williams RA, Minekus MP. et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 2001; 193: 147-54.
• 29 Nakamura Y, Yasuoka H, Tsujimoto M. et al. Prognostic significance of vascular endothelial growth factor d in breast carcinoma with long-term follow-up. Clin Cancer Res 2003; 9: 716-21.
• 30 Yokoyama Y, Charnock-Jones DS, Licence D. et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003; 88: 237-44.
• 31 White JD, Hewett PW, Kosuge D. et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002; 62: 1669-75.
• 32 Kinoshita J, Kitamura K, Kabashima A. et al. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001; 66: 159-64.
• 33 Yang W, Klos K, Yang Y. et al. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94: 2855-61.
• 34 Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29: 231-45.
• 35 Niki T, Iba S, Tokunou M. et al. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000; 6: 2431-9.
• 36 O-Charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 2001; 92: 556-68.
• 37 Orpana A, Salven P. Angiogenic and lymphangiogenic molecules in hematological malignancies. Leuk Lymphoma 2002; 43: 219-24.
• 38 Masood R, Kundra A, Zhu S. et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003; 104: 603-10.
• 39 Fielder W, Graeven U, Ergun S. et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997; 11: 1234-7.
• 40 de Waal RM, van Altena MC, Erhard H. et al. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. Am J Pathol 1997; 150: 1951-7.
• 41 Padera TP, Kadambi A, di Tomaso E. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296: 1883-6.
• 42 Schoppmann SF, Birner P, Stockl J. et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 947-56.
• 43 Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003; 9: 250-6.
• 44 Beasley NJ, Prevo R, Banerji S. et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002; 62: 1315-20.
• 45 Niki T, Iba S, Yamada T. et al. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adeno-carcinoma. J Pathol 2001; 193: 450-7.
• 46 Skobe M, Hamberg LM, Hawighorst T. et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159: 893-903.
• 47 Narko K, Enholm B, Makinen T. et al. Effect of inflammatory cytokines on the expression of the vascular endothelial growth factor-C. Int J Exp Pathol 1999; 80: 109-12.
• 48 Kurebayashi J, Otsuki T, Kunisue H. et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999; 90: 977-81.
• 49 Yokoyama Y, Sato S, Futagami M. et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 2000; 77: 413-8.
• 50 Yonemura Y, Fushida S, Bando E. et al. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 2001; 37: 918-23.
• 51 Okamoto M, Nishimine M, Kishi M. et al. Prediction of delayed neck metastasis in patients with stage I/II squamous cell carcinoma of the tongue. J Oral Pathol Med 2002; 31: 227-33.
• 52 Birner P, Obermair A, Schindl M. et al. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 2001; 7: 93-7.
• 53 Schoppmann SF, Schindl M, Breiteneder-Geleff S. et al. Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer. Anticancer Res 2001; b 21: 3419-23.
• 54 Schoppmann SF, Birner P, Studer P. et al. Lymphatic microvessel density and lympho-vascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 2001; a 21: 2351-5.
• 55 Nathanson SD, Zarbo RJ, Wachna DL. et al. Microvessels that predict axillary lymph node metastases in patients with breast cancer. Arch Surg 2000; 135: 586-593. discussion 593-84
• 56 Mandriota SJ, Jussila L, Jeltsch M. et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Embo J 2001; 20: 672-82.
• 57 Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315: 115-22.
• 58 Gannon G, Mandriota SJ, Cui L. et al. Overexpression of vascular endothelial growth factor-A165 enhances tumor angio-genesis but not metastasis during beta-cell carcinogenesis. Cancer Res 2002; 62: 603-8.
• 59 Krishnan J, Kirkin V, Steffen A. et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 2003; 63: 713-22.
• 60 Mattila MM, Ruohola JK, Karpanen T. et al. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in ortho-topic MCF-7 tumors. Int J Cancer 2002; 98: 946-51.
• 61 Skobe M, Hawighorst T, Jackson DG. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-8.
• 62 Stacker SA, Caesar C, Baldwin ME. et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.
• 63 Karpanen T, Egeblad M, Karkkainen MJ. et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-90.
• 64 He Y, Kozaki K, Karpanen T. et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002; 94: 819-25.
• 65 Leu AJ, Berk DA, Lymboussaki A. et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60: 4324-7.
• 66 Hartveit E. Attenuated cells in breast stroma: the missing lymphatic system of the breast. Histopathology 1990; 16: 533-43.
• 67 Kirkin V, Mazitschek R, Krishnan J. et al. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem 2001; 268: 5530-40.
• 68 Tanaka K, Sonoo H, Kurebayashi J. et al. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin Cancer Res 2002; a 8: 1125-31.
• 69 Bunone G, Vigneri P, Mariani L. et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999; 155: 1967-76.
• 70 Yonemura Y, Endo Y, Fujita H. et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999; 5: 1823-9.
• 71 Takahashi A, Kono K, Itakura J. et al. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 2002; 62: 121-7.
• 72 Ichikura T, Tomimatsu S, Ohkura E. et al. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 2001; 78: 132-7.
• 73 Kabashima A, Maehara Y, Kakeji Y. et al. Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma. Oncology 2001; 60: 146-50.
• 74 Kajita T, Ohta Y, Kimura K. et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001; 85: 255-60.
• 75 Ohta Y, Nozawa H, Tanaka Y. et al. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2000; 119: 804-13.
• 76 Arinaga M, Noguchi T, Takeno S. et al. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with non-small cell lung carcinoma. Cancer 2003; 97: 457-64.
• 77 Kaio E, Tanaka S, Kitadai Y. et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003; 64: 61-73.
• 78 Akagi K, Ikeda Y, Miyazaki M. et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000; 83: 887-91.